WO2003032961A3 - Methods for preventing and treating bone loss with steroid compounds - Google Patents

Methods for preventing and treating bone loss with steroid compounds Download PDF

Info

Publication number
WO2003032961A3
WO2003032961A3 PCT/EP2002/011123 EP0211123W WO03032961A3 WO 2003032961 A3 WO2003032961 A3 WO 2003032961A3 EP 0211123 W EP0211123 W EP 0211123W WO 03032961 A3 WO03032961 A3 WO 03032961A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
methods
bone loss
treating bone
steroid compounds
Prior art date
Application number
PCT/EP2002/011123
Other languages
French (fr)
Other versions
WO2003032961A2 (en
Inventor
Salle Enrico Di
Giorgio Massimini
Colin Lowery
Paul Edward Goss
Original Assignee
Pharmacia Italia Spa
Upjohn Co
Salle Enrico Di
Giorgio Massimini
Colin Lowery
Paul Edward Goss
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa, Upjohn Co, Salle Enrico Di, Giorgio Massimini, Colin Lowery, Paul Edward Goss filed Critical Pharmacia Italia Spa
Priority to NZ532064A priority Critical patent/NZ532064A/en
Priority to BR0213162-5A priority patent/BR0213162A/en
Priority to CA002463142A priority patent/CA2463142A1/en
Priority to MXPA04003405A priority patent/MXPA04003405A/en
Priority to EP02801313A priority patent/EP1435967A2/en
Priority to JP2003535765A priority patent/JP2005508958A/en
Priority to IL16116202A priority patent/IL161162A0/en
Publication of WO2003032961A2 publication Critical patent/WO2003032961A2/en
Publication of WO2003032961A3 publication Critical patent/WO2003032961A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Abstract

A method of preventing and treating abnormal metabolic bone disorders in a postmenopausal or oophorectomized woman is disclosed, which comprises administering to said an effective amount of exemestane or 17-hydro-exemestane, alone or in combination with additional therapeutic agents.
PCT/EP2002/011123 2001-10-10 2002-09-30 Methods for preventing and treating bone loss with steroid compounds WO2003032961A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
NZ532064A NZ532064A (en) 2001-10-10 2002-09-30 Methods for preventing and treating bone loss with steroid compounds
BR0213162-5A BR0213162A (en) 2001-10-10 2002-09-30 Methods for the prevention and treatment of bone loss with steroid compounds.
CA002463142A CA2463142A1 (en) 2001-10-10 2002-09-30 Methods for preventing and treating bone loss with steroid compounds
MXPA04003405A MXPA04003405A (en) 2001-10-10 2002-09-30 Methods for preventing and treating bone loss with steroid compounds.
EP02801313A EP1435967A2 (en) 2001-10-10 2002-09-30 Methods for preventing and treating bone loss with steroid compounds
JP2003535765A JP2005508958A (en) 2001-10-10 2002-09-30 Methods for preventing and treating bone loss with steroid compounds
IL16116202A IL161162A0 (en) 2001-10-10 2002-09-30 Methods for preventing and treating bone loss with steroid compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32820901P 2001-10-10 2001-10-10
US60/328,209 2001-10-10

Publications (2)

Publication Number Publication Date
WO2003032961A2 WO2003032961A2 (en) 2003-04-24
WO2003032961A3 true WO2003032961A3 (en) 2003-09-04

Family

ID=23279989

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/011123 WO2003032961A2 (en) 2001-10-10 2002-09-30 Methods for preventing and treating bone loss with steroid compounds

Country Status (12)

Country Link
EP (1) EP1435967A2 (en)
JP (1) JP2005508958A (en)
KR (1) KR20050032507A (en)
CN (1) CN1713915A (en)
BR (1) BR0213162A (en)
CA (1) CA2463142A1 (en)
IL (1) IL161162A0 (en)
MX (1) MXPA04003405A (en)
NZ (1) NZ532064A (en)
PL (1) PL370080A1 (en)
WO (1) WO2003032961A2 (en)
ZA (1) ZA200402734B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
WO2005027916A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors
US7332482B2 (en) 2003-09-24 2008-02-19 Bioxell S.P.A. Method for treating benign prostatic hyperplasia
CA2605796A1 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CA2800673A1 (en) 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9187460B2 (en) 2011-12-14 2015-11-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
PL3929196T3 (en) 2013-09-24 2023-12-11 Fujifilm Corporation Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof
EP3294716B1 (en) 2015-12-30 2020-04-15 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307135A1 (en) * 1987-09-11 1989-03-15 FARMITALIA CARLO ERBA S.r.l. 17-substituted androsta-1,4-dien-3-one derivatives
US5663195A (en) * 1994-10-19 1997-09-02 Merck & Co., Inc. Method of preventing bone loss
WO1998033919A2 (en) * 1997-01-30 1998-08-06 Ixsys, Incorporated Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use
WO2000002553A1 (en) * 1998-07-08 2000-01-20 Lipogenics, Inc. Compositions and methods for treating and preventing bone diseases using tocotrienols
WO2001012206A2 (en) * 1999-08-13 2001-02-22 Heinrich Wieland Soy-glycine extracts and aromatase inhibitors for positively influencing collagen

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307135A1 (en) * 1987-09-11 1989-03-15 FARMITALIA CARLO ERBA S.r.l. 17-substituted androsta-1,4-dien-3-one derivatives
US5663195A (en) * 1994-10-19 1997-09-02 Merck & Co., Inc. Method of preventing bone loss
WO1998033919A2 (en) * 1997-01-30 1998-08-06 Ixsys, Incorporated Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use
WO2000002553A1 (en) * 1998-07-08 2000-01-20 Lipogenics, Inc. Compositions and methods for treating and preventing bone diseases using tocotrienols
WO2001012206A2 (en) * 1999-08-13 2001-02-22 Heinrich Wieland Soy-glycine extracts and aromatase inhibitors for positively influencing collagen

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GOSS P ET AL: "The effects of exemestane on bone and lipids in the ovariectomized rat.", BREAST CANCER RESEARCH AND TREATMENT, vol. 69, no. 3, October 2001 (2001-10-01), 24th Annual San Antonio Breast Cancer Symposium;San Antonio, Texas, USA; December 10-13, 2001, October, 2001, pages 224, XP008012823, ISSN: 0167-6806 *
GOSS PAUL: "Anti-aromatase agents in the treatment and prevention of breast cancer.", CANCER CONTROL, (2002 MAR-APR) 9 (2 SUPPL) 2-8. REF: 28, XP001133770 *
PYTLIK M ET AL: "Effects of formestane on development of osteopenia caused by ovariectomy in rats.", CALCIFIED TISSUE INTERNATIONAL, vol. 64, no. SUPPL. 1, 1999, XXVIth European Symposium on Calcified Tissues;Maastricht, Netherlands; May 7-11, 1999, pages S68, XP008012825, ISSN: 0171-967X *
ZILEMBO N ET AL: "Markers of bone turnover in metastatic breast cancer (MBC) patients having progressed on tamoxifen: Short term effect of further treatment with either exemestane (EXE) or megestrol acetate (MA).", EUROPEAN JOURNAL OF CANCER, vol. 37, no. Supplement 6, 23 October 2001 (2001-10-23), 11th European Cancer Conference;Lisbon, Portugal; October 21-25, 2001, October, 2001, pages S193 - S194, XP001133767, ISSN: 0959-8049 *

Also Published As

Publication number Publication date
IL161162A0 (en) 2004-08-31
ZA200402734B (en) 2005-01-13
CA2463142A1 (en) 2003-04-24
CN1713915A (en) 2005-12-28
WO2003032961A2 (en) 2003-04-24
KR20050032507A (en) 2005-04-07
JP2005508958A (en) 2005-04-07
BR0213162A (en) 2004-09-14
EP1435967A2 (en) 2004-07-14
PL370080A1 (en) 2005-05-16
MXPA04003405A (en) 2004-06-18
NZ532064A (en) 2006-04-28

Similar Documents

Publication Publication Date Title
IL131477A0 (en) Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
TW200505901A (en) Muscarinic agonists
WO2001028491A3 (en) Method and composition for the treatment of dermatologic diseases
CA2367092A1 (en) Method for treating and/or preventing retinal diseases with sustained release corticosteroids
WO2003072040A3 (en) Administration of agents for the treatment of inflammation
EP1555025A3 (en) Use of dehydroepiandrosterone analogs for the treatment of asthma
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
TWI255713B (en) Method for treating meibomian gland disease
WO1999046279A3 (en) INHIBITORS OF TYPE 5 AND TYPE 3 17β-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
WO2004037205A3 (en) LOW DOSE METHODS FOR TREATING DISORDERS IN WHICH TNFα ACTIVITY IS DETRIMENTAL
BR0212252A (en) Methods to Reduce Hypertension and Heart Failure in a Mammal
MXPA04000654A (en) Dermal therapy using phosphate derivatives of electron transfer agents.
WO2002058706A3 (en) Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
WO2001024783A3 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
WO2001068053A3 (en) Methods and compositions for treating and preventing posterior segment ophthalmic disorders
WO2003032961A3 (en) Methods for preventing and treating bone loss with steroid compounds
WO2002072106A3 (en) Combined method for treating hormono-dependent disorders with exemestane
WO2003049667A3 (en) The method of treating cancer
JP2003528919A5 (en)
BR0309032A (en) Method to Treat Vasomotor Symptoms, Menopause, Hormonal Deficiencies in a Patient, and to Treat a Patient Suffering from Vasomotor Symptoms

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 161162

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 532064

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002801313

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004/02734

Country of ref document: ZA

Ref document number: 2463142

Country of ref document: CA

Ref document number: 200402734

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003535765

Country of ref document: JP

Ref document number: 1020047005231

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20028201167

Country of ref document: CN

Ref document number: PA/a/2004/003405

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002333895

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500505

Country of ref document: PH

WWP Wipo information: published in national office

Ref document number: 2002801313

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 532064

Country of ref document: NZ

WWW Wipo information: withdrawn in national office

Ref document number: 2002801313

Country of ref document: EP